Abstract

Combination therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose 
cotransporter 2 inhibitors (SGLT2 inhibitors) has emerged as a strategic approach for glycemic control, weight 
management, and cardiovascular risk modification in type 2 diabetes (T2D). The mechanistic complementarity of 
incretin-based signaling and renal glucose excretion offers potential synergistic benefits beyond monotherapy, but 
the magnitude, consistency, and safety of such synergy require critical appraisal. This paper aimed to synthesize 
mechanistic, analytical, clinical, and translational evidence on GLP-1 RA and SGLT2 inhibitor combination therapy 
in T2D, identify optimal clinical contexts, and delineate gaps warranting future research. A structured literature 
search of electronic databases (PubMed, Embase, ClinicalTrials.gov) for peer‑reviewed studies and guidelines from 
2010 to 2024 was conducted, prioritizing randomized controlled trials, meta-analyses, and high‑quality 
observational studies. Inclusion criteria encompassed adult T2D patients treated with GLP‑1 RAs in combination 
with SGLT2 inhibitors, with reporting on glycemic, weight, cardiovascular, and safety outcomes. Across trials, 
combination therapy produced greater reductions in HbA1c and weight versus either agent alone, with 
heterogeneous effects on blood pressure and lipids. Cardiovascular and renal outcomes were broadly favorable, 
though event rates and duration varied. Safety signals included increased gastrointestinal symptoms and, less 
consistently, risk of hypoglycemia in certain regimens, with preserved or improved renal function in most cohorts. 
Crucial interactions include additive glycemic effects, potential bile acid–mediated metabolic modulation, and 
potential attenuation of GLP‑1 RA–related gastrointestinal intolerance by dose-titration strategies. GLP‑1 RA and 
SGLT2 inhibitor combination therapy offered synergistic metabolic and cardiometabolic benefits in select T2D 
populations, particularly where weight reduction and cardiovascular risk mitigation are priorities, but patient 
selection, sequencing, and monitoring strategies must be individualized, given heterogeneity in responses and safety 
profiles.